Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO ROUND-UP: Invuity and Endochoice lower the bar, but IPO hopefuls keep coming

This article was originally published in Clinica

Executive Summary

Lowering one’s expectations is becoming the unfortunate norm when it comes to medtech IPOs. Since last month, Clinica has added two more downsized public market debuts, which means of the 13 completed IPOs recorded for the year to date, nine raised less money than they had initially hoped (see Table 1). The two new additions to Clinica’s IPO tracker are Invuity and EndoChoice, both in the field of minimally invasive surgery.

You may also be interested in...



Boston Scientific Buys EndoChoice, Mulls De-FUSEing Potential Weakness

Boston Scientific is making a significant investment in its endoscopy portfolio as it strikes a $210m deal to buy colonoscopy specialist EndoChoice. The Natick, Massachusetts, group added that it will be “evaluating strategic options” for EndoChoice’s Fuse colonoscope.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Topics

UsernamePublicRestriction

Register

MT102674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel